Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODC-IL2 in advanced solid tumors
NCT06770764Phase 1Recruiting
- Sponsor
- Trutino Biosciences
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of ODC-IL2 in solid tumor (advanced stage) and metastatic solid tumors (2 arms), sponsored by Trutino Biosciences. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Incidence of Treatment-Emergent Adverse Events and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
ODC-IL2
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT06770764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770764.